Skip to content

To evaluate the Safety and efficacy of Unani formulations Zimad e Bars in Kalaf (Melasma)

Clinical Validation study on ŪnÄ?nÄ« Pharmacopoeial Formulationâ?? Zimad e Bars in Kalaf (Melasma)

Status
Recruiting
Phases
Phase 2
Study type
Interventional
Source
CTRI
Registry ID
CTRI/2015/11/006385
Enrollment
300
Registered
2015-11-26
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: L811- Chloasma Health Condition 2: null- Kalaf (Melasma)

Interventions

Intervention1: Ointment Zimaad e Baras: Ointment Zimaad e Baras Local Application Q.S. Twice daily for 8 weeks Control Intervention1: nil: nil

Sponsors

Central Council for Research in Unani Medicine
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: Female Subjects with 18 to 65 years of age The patient presenting anyone or all signs mentioned below. 1. Ill defined light brown to grey brown macules on Forehead 2. Ill defined light brown to grey brown macules in RMR 3. Ill defined light brown to grey brown macules in LMR 4. Ill defined light brown to grey brown macules on Chin

Exclusion criteria

Exclusion criteria: Patients with anyone of the following skin disease • Bahaq Aswad (pitryasis nigra) o Namash (Naevus). o Barash (lentigo) o KhÄ«lÄ?n (mole) o Nishanate Quruh o Fitzpatrick skin type grade 1 & 2 • Any systemic disorder requiring long term treatment. • Drug or alcohol addict • Subjects with oral contraceptive pills (OCPs) • Pregnant and lactating woman • Those who refuse to avoid cosmetics during study period Subject Selection • Female subjects with 18 to 65 years of age • The patient presenting anyone or all signs mentioned below. 1. Ill defined light brown to grey brown macules on Forehead 2. Ill defined light brown to grey brown macules in RMR 3. Ill defined light brown to grey brown macules in LMR 4. Ill defined light brown to grey brown macules on Chin

Design outcomes

Primary

MeasureTime frame
Improvement in signs and symptoms of Zimad e Bars in Kalaf (Melasma)Timepoint: 8 weeks

Secondary

MeasureTime frame
Haematological and biochemical assessment for safety assessmentTimepoint: 8 weeks

Countries

India

Contacts

Public ContactDr Pradeep Kumar

Central Council for Research in Unani Medicine (CCRUM)

ccrum507@gmail.com9810161758

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026